FDA Approved 100 ANDAs in 2021 for Originator Drugs With Inadequate Generic Competition

The FDA approved 100 abbreviated new drug applications (ANDAs) through its congressionally established Competitive Generic Therapy (CGT) pathway in 2021, bringing 100 new low-priced medicines to the market for originator…

Continue ReadingFDA Approved 100 ANDAs in 2021 for Originator Drugs With Inadequate Generic Competition

ICER Says Payers Should Consider Eli Lilly’s Type 2 Diabetes Drug Candidate — If the Price is Right

The Institute for Clinical and Economic Review (ICER) has weighed in on Eli Lilly’s type 2 diabetes drug candidate tirzepatide, saying payers should consider broadening coverage to GLP-1 RAs and…

Continue ReadingICER Says Payers Should Consider Eli Lilly’s Type 2 Diabetes Drug Candidate — If the Price is Right